<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867033</url>
  </required_header>
  <id_info>
    <org_study_id>ALTITUDES-1508</org_study_id>
    <nct_id>NCT02867033</nct_id>
  </id_info>
  <brief_title>National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)</brief_title>
  <acronym>ALTITUDES</acronym>
  <official_title>National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Timone</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to constitute the French largest Aggressive fibromatosis cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aggressive fibromatosis (AF) is a rare non-metastasizing connective tissue tumor (&lt; 300&#xD;
      cases/year in France), associated with high risk of local relapse, functional impairment and&#xD;
      pain. AF can occur at any age, but most commonly between 25 and 40 with a significant female&#xD;
      predominance. AF is most frequently (about 85%) sporadic and then associated with a somatic&#xD;
      mutation of the CTNNB1 gene. AF is associated with heredity condition, as complication of&#xD;
      familial adenomatous polyposis (with germinal mutation of Adenomatous polyposis coli (APC)&#xD;
      gene). Most of AF arises on lims or abdominal wall. Nevertheless, some particular locations&#xD;
      are life-threatening (mesenteric or cervical locations). The natural course of AF is&#xD;
      unpredictable. One third of tumors are spontaneously stable. One third of tumor spontaneously&#xD;
      decreases. One third of tumor is progressive, with a non-linear tumor growth dynamic. As the&#xD;
      consequence the decision making for starting curative intent treatment is difficult, since&#xD;
      some treatment could be mutilating (large en bloc surgery) or associated with late and severe&#xD;
      complications (radiotherapy) and since these treatments could fail to control this benign&#xD;
      tumor. Therapeutic options are: wait-and-see policy, surgery (sometimes mutilating),&#xD;
      radiotherapy or systemic treatment (non-steroidal anti-inflammatory drugs, hormonotherapy,&#xD;
      imatinib, chemotherapy). Level of evidence associated these options is very low, based on&#xD;
      retrospective studies and rare non-randomized phase II clinical trials.&#xD;
&#xD;
      Regarding these uncertainties, physicians can hardly answer to patient questions.&#xD;
&#xD;
      Prospective data provided by a large multi-center cohort is needed. The objective of the&#xD;
      present study is to create a large cohort of incident cases of AF associated with tumor bank&#xD;
      and collection of blood samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2016</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident cases of aggressive fibromatosis, diagnosed after 01/01/2016 in France</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To constitute, at a national level, the largest cohort of incident cases of desmoid tumours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Aggressive Fibromatosis associated with familial adenomatous polyposis</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To describe and analyse the link between Aggressive Fibromatosis and familial adenomatous polyposis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CTNNB1 mutation in non-selected cases of Aggressive Fibromatosis</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To describe the proportion of AF cases characterized by CTNNB1 somatic mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Management of AF</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Description of the management of AF. Study of prognosis factor for progressive disease and death. Study of tumor response to treatments (Best response and progression-free survival) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>at baseline, one year</time_frame>
    <description>To describe the psychological impact of the disease at diagnosis and a year after diagnosis. And to compare changes between the time of diagnosis and one year after the treatments used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire (QLQC30)</measure>
    <time_frame>at baseline, one year</time_frame>
    <description>To describe the consequences of the disease on the quality of life at diagnosis and a year after diagnosis. And to compare changes between the time of diagnosis and one year after the treatments used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of pregnancy and hormonal exposure</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>To study the impact of pregnancy and hormonal exposure on the evolution of the disease according to recurrence/progression rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of polyposis and colorectal cancer</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Rate of polyposis and colorectal cancer in the AF population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mutation rate of APC</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To determine the mutation rate of APC at constitutional and somatic levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Mutation rate of CTNNB1</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To determine the mutation rate of CTNNB1 at constitutional and somatic levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between APC and CTNNB1 mutations rates</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To demonstrate that APC and CTNNB1 mutations are two mutually exclusive molecular alterations</description>
  </other_outcome>
  <other_outcome>
    <measure>APC mutation rate</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To correlate mutational somatic and constitutional rate of APC gene</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of other mutations</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To search other molecular anomalies for patients without APC or CTNNB1 mutations (10 % of cases)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cell free (circulating) nucleic acid extraction technics</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To determine sensibility and specificity of cell free (circulating) nucleic acid extraction techniques</description>
  </other_outcome>
  <other_outcome>
    <measure>AF outcome</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To describe patient outcomes and identify prognostic factors</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment response</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To search for factors involved in response treatment prediction</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">628</enrollment>
  <condition>Aggressive Fibromatosis</condition>
  <arm_group>
    <arm_group_label>Study procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>pre-therapeutic or post-therapeutic biopsy or resected tissues</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biobank constitution</intervention_name>
    <description>Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coloscopy</intervention_name>
    <description>For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling (facultative)</intervention_name>
    <description>Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pain evaluation</intervention_name>
    <description>Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biobank realization</intervention_name>
    <description>Realization of a tumor biobank is part of classical procedure of participating centers</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Incident Case of aggressive fibromatosis in France, diagnosed after 01/01/2016&#xD;
&#xD;
          -  Confirmed diagnosis by the French anatomopathological diagnosis network (including&#xD;
             search for mutation of the β-Catenin Gene, CTNNB1)&#xD;
&#xD;
          -  Affiliation to the National Health System&#xD;
&#xD;
          -  Informed consent signed (both parents signature for non adult patients)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Administrative or legal measure of liberty privation&#xD;
&#xD;
          -  Patient not able to give consent or unwilling to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas PENEL, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sébastien SALAS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Timone adultes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen-Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble- Hôpital Couple Enfant</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital la Timone Enfants Service Oncologie Pédiatrique</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital la Timone Service Oncologie Médicale</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère Enfant - CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Département Oncologie Médicale</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Département Oncologie Pédiatrique</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpîtal d'Enfants Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes- Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35023</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie-Hôpital René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Étienne - Hôpital Nord</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Enfants- CHU Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>desmoid tumour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibroma</mesh_term>
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

